



Tuberculosis today: Where do we stand in Germany, Europe and globally? Analysis of surveillance data

Vahur Hollo
European Centre for Disease Prevention and Control
Düsseldorf, 14 February 2017


Outline



- TB in the world
- TB in Europe and Germany
 - EU/EEA surveillance
 - Key epidemiological findings
- Summary

Estimated TB incidence rates, 2015





• 11% HIV positive

EU/EEA surveillance of TB

- Annual collection of case-based data from 28 EU Member States, Iceland and Norway
 - Demographics, TB site, treatment history, lab confirmation, HIV status, drug susceptibility*, treatment outcome
- Harmonisation across countries through standard EU case definition (and WHO definitions), reporting protocol and lab EQA
- Thorough data validation with providers
- Dissemination through
 - ECDC Surveillance Atlas
 - Annual enhanced surveillance report (jointly with WHO/Europe)
 - Scientific articles



EU28 + 2 EEA



Data collection

TESSy & WHO Global TB database

Data validation



Data analysis

Reporting

TB notifications, EU/EEA, 2015



60 195 TB cases notified in 30 EU/EEA countries Notification rate of 11.7 per 100 000 population (range 2.1–76.5)


< 5 per 100 000

5 to 9 per 100 000

10 to 19 per 100 000

20 to 49 per 100 000

≥ 50 per 100 000




TB notifications (number and rate) by year, EU/EEA, 1995-2015



Steady decline between 1995 and 2015:

- number of TB cases decreased by 45%
- notification rate decreased by 49%



Annual change in TB notification rates, EU/EEA, 1995 - 2015




Average notification rate per 100 000 population declined **3.3** percent annually (range - 7.7% to 5.2%)



-5 to -2%


-2 to 0%

> 0%



Confirmed TB cases*, EU/EEA, 2015








< 60%

60 to 69%

70 to 79%


≥ 80%



Confirmed TB cases (number and %) by year *, EU/EEA, 1995-2015



Percentage of "laboratory-confirmed" cases increased from 41.5% in 1995 to 66.9 % in 2015




Tuberculosis caused by M. bovis, 2015

- ecoc
- 14 pathogens of human diseases are collected and analysed in the zoonoses report by ECDC including *M. bovis* human cases
- 171 confirmed human cases caused by M. bovis in 2015 in EU/EEA, 0.03 cases per 100 000 population
- There was no clear association between a country's OTF status (OTF; Officially bovine tuberculosis free in cattle) and its notification rate in humans


Tuberculosis caused by *M. bovis*, EU/EEA 2015





Extrapulmonary TB cases, EU/EEA, 2015





Percentage of previously treated TB cases by country, EU/EEA, 2015






300

< 5%

5 to 9.9%

10 to 14.9%

≥ 15%



TB in children under 15, EU/EEA, 2015



2 444 TB cases reported in children under 15 years. That is

4.1% of all TB cases (range 0-21.1%) and

3.0 notifications per 100 000 child population (range 0-21.3)



Cases per 100 000 child


< 1

1 to 1.9

2 to 3.9

4 to 9.9

≥ 10



TB cases in persons of foreign origin, EU/EEA, 2015



29.8% of TB cases occurred in persons of foreign origin (range 0.2–89.5%)




< 1%

1 to 9.9%

10 to 49.9%

50 to 74.9%

≥ 75%




Notified TB cases in persons of foreign origin, EU/EEA, 2006 — 2015



Percentage of cases in persons of foreign origin increased from **18%** in 2006 to **30%** in 2015.

Rate per 100 000 total population is stable between **3.1** and **3.5**




Source: Surveillance Atlas of Infectious Diseases

TB cases of EU/EEA, non-EU/EEA and unknown origin by year, 2007 – 2013



Percentage of TB cases of foreign origin outside of EU/EEA increased from **13.6%** in 2007 to **21.8%** in 2013



Source: Ködmön C, et al. Euro Surveill. 2016

TB cases originating from other EU/EEA countries, 2007 - 2013



12 566 TB cases reported to originate from another **EU/EEA** country Percentage of cases diagnosed in persons of foreign origin increased from 1.7% in 2007 to 3.3% in 2013



TB cases originating from country reported by other EU/EEA **Member States**

country originating

from other EU/EEA

Member States



Source: Hollo V, et al. Euro Surveill. 2016

Percentage of multidrug-resistant TB by country, EU/EEA, 2015



4.1% of TB cases with DST* results were multidrug-resistant (range 0–21.2%)



< 1%

1 to 1.9%

2 to 4.9%

5 to 9.9%


≥ 10%



Multidrug-resistant TB cases (number and rate) by year, EU/EEA, 1995 – 2015



Notification rate in MDR TB cases stabilized at 0.3 per 100 000 population



Source: Surveillance Atlas of Infectious Diseases 20

Extensively drug-resistant TB among MDR TB cases by country, EU/EEA, 2015



19.7% of MDR TB cases with 2nd line DST* were extensively drug-resistant (range 0–30% and 13–25.4% for countries reporting more than five cases)




< 1%

1 to 9.9%

10 to 14.9%

15 to 24.9%


≥ 25%



Percentage of TB/HIV co-infection by country, EU/EEA, 2015



4.6% of TB cases with known HIV status* were HIV-positive (range 0–22.6%)



< 1%

1 to 9.9%

10 to 14.9%

≥ 15%

Tuberculosis and HIV co-infection in Europe: looking a one reality from two angles

ecoc


Testing of TB cases for HIV and of HIV cases for TB of crucial importance, especially for:

N (%) N (%) Odds Ratio (95% CI)							
Total 1 028 (4.9) 19 791 (95.1) Gender (N=20 810) Male	Variable		HIV-positive TB cases		HIV-negative TB cases	1	
Gender (N=20 810) Male Male Female 736 (5.2) 13 305 (94.8) 1.25 (1.07-1.46) Age groups (N=20 815) 0-14 2 (0.3) 705 (99.7) 0.03 (0.01-0.12) 15-24 82 (3.6) 2 201 (96.4) 0.45 (0.35-0.57) 25-44 641 (8.3) 7 088 (91.7) 1 45-64 281 (4.0) 6 694 (96.0) 0.43 (0.36-0.50) 265 21 (0.7) 3 100 (99.3) 0.07 (0.04-0.11) Region of origin (N=20 163) Europe - Non EU/EEA 787 (4.2) 17 940 (95.8) 1.91 (1.15-3.17) 19 (8.5) 205 (91.5) 3.28 (2.35-4.57) 18 (8.1) 204 (91.5) 3.28 (2.35-4.57) 18 (8.1) 204 (91.5) 1.39 (1.16-1.66) 190 (5.8) 3 065 (94.8) 1.39 (1.16-1.66)			N (%)		N (%)	Odds Ratio (95% CI)	
Male 736 (5.2) 13 305 (94.8) Age groups (N=20 815) 0-14 2 (0.3) 705 (99.7) 0.03 (0.01-0.12) 15-24 82 (3.6) 2 201 (96.4) 0.45 (0.35-0.57) 25-44 641 (8.3) 7 088 (91.7) 1 45-64 281 (4.0) 6 694 (96.0) 0.43 (0.36-0.50) ≥65 21 (0.7) 3 100 (99.3) 0.07 (0.04-0.11) Region of origin (N=20 163) Europe - Non EU/EEA 787 (4.2) 17 940 (95.8) 1.91 (1.15-3.17) 19 (8.5) 205 (91.8) 3.28 (2.35-4.57) 18 (8.1) 204 (91.9) 1.4 (0.00-2.00) Other regions 25 (3.7) 649 (96.3) 0.64 (0.42-0.98) Previously treated 796 (4.6) 16 537 (95.8) 1.39 (1.16-1.66) 190 (5.8) 3 065 (94.8)	Total		1 028 (4.9)		19 791 (95.1)		
Female 291 (4.3) 6 478 (95.] 1.25 (1.07-1.46)	Gender (N=20 810)						
Female 291 (4.3) 6 478 (95.] 1.25 (1.07-1.46)	Male	Male	736 (5.2)		13 305 (94.8	1 25 /1 07 1 46\	
Age groups (N=20 815) O-14 2 (0.3) 705 (99.7) 0.03 (0.01-0.12)		Female	291 (4.3)			1.25 (1.07-1.46)	
0-14 2 (0.3) 705 (99.7) 0.03 (0.01-0.12) 15-24 82 (3.6) 2 201 (96.4) 0.45 (0.35-0.57) 25-44 641 (8.3) 7 088 (91.7) 1 45-64 281 (4.0) 6 694 (96.0) 0.43 (0.36-0.50) ≥65 21 (0.7) 3 100 (99.3) 0.07 (0.04-0.11) Region of origin (N=20 163) Europe - Non EU/EEA Africa 787 (4.2) 19 (8.5) 205 (91.5 19 (8.5) 204 (91.5) 3.28 (2.35-4.57) Other regions 25 (3.7) 649 (96.3) 0.64 (0.42-0.98) Previously treated 796 (4.6) 16 537 (95. 1.39 (1.16-1.66) 190 (5.8) 3 065 (94.	Age groups (N=20 815)						
15-24 82 (3.6) 2 201 (96.4) 0.45 (0.35-0.57) 25-44 641 (8.3) 7 088 (91.7) 1 45-64 281 (4.0) 6 694 (96.0) 0.43 (0.36-0.50) ≥65 21 (0.7) 3 100 (99.3) 0.07 (0.04-0.11) Region of origin (N=20 163) Europe - Non EU/EEA Africa 787 (4.2) 17 940 (95.8 205 (91.8 56 (17.7) 260 (82.3 56 (17.7) 260 (82.3 56 (17.7) 204 (91.5) 3.28 (2.35-4.57) Other regions 25 (3.7) 649 (96.3) 0.64 (0.42-0.98) Previously treated 796 (4.6) 16 537 (95. 190 (5.8) 3 065 (94. 1.39 (1.16-1.66)			2 (0.3)		705 (99.7)	0.03 (0.01-0.12)	
25-44 641 (8.3) 7 088 (91.7) 1 45-64 281 (4.0) 6 694 (96.0) 0.43 (0.36-0.50) ≥65 21 (0.7) 3 100 (99.3) 0.07 (0.04-0.11) Region of origin (N=20 163) Europe - Non EU/EEA Africa 787 (4.2) 17 940 (95.8 205 (91.8 205 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (91.8 204 (15-24			<u>`</u>	<u> </u>	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	25-44						
Europe - Non EU/EEA 787 (4.2) 17 940 (95.8 1.91 (1.15-3.17) 3 100 (99.3) 1.91 (1.15-3.17) 3 100 (99.3) 1.91 (1.15-3.17) 19 (8.5) 205 (91.5 1.91 (1.15-3.17) 3 100 (99.3) 1.91 (1.15-3.17) 3 100 (99.3) 1.91 (1.15-3.17) 19 (8.5) 205 (91.5 1.91 (1.15-3.17) 3 100 (99.3) 1.91 (1.15-3.17) 3 100 (99.3) 1.91 (1.15-3.17) 19 (8.5) 205 (91.5 1.91 (1.15-3.17) 3 100 (99.3) 1.91 (1.15-3.17) 3 100 (99.3) 1.91 (1.15-3.17) 19 (8.5) 18 (8.1) 204 (91.9) 1.91 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.17) 19 (1.15-3.	45-64						
Region of origin (N=20 163) Europe - Non EU/EEA 787 (4.2) 17 940 (95.8) 1.91 (1.15-3.17) Africa 56 (17.7) 260 (82.3) 1.91 (1.15-3.17) 3.28 (2.35-4.57) 1.91 (1.15-3.17) 3.28 (2.35-4.57) 3.28 (2.35-4.57) 1.92 (1.16-1.66) Previously treated 796 (4.6) 16 537 (95.) 1.39 (1.16-1.66) 1.39 (1.16-1.66)	≥65						
Africa 19 (8.5) 205 (91.5) 56 (17.7) 260 (82.5) 3.28 (2.35-4.57) 18 (8.1) 204 (91.5) 649 (96.3) 0.64 (0.42-0.98) 190 (5.8) 3 065 (94.5) 1.39 (1.16-1.66)							
Africa 19 (8.5) 205 (91.5) 56 (17.7) 260 (82.5) 3.28 (2.35-4.57) 18 (8.1) 204 (91.5) 649 (96.3) 0.64 (0.42-0.98) 190 (5.8) 3 065 (94.5) 1.39 (1.16-1.66)	Furono Non EU/EEA 1 01 /1 15 2 17						
Atrica 56 (17.7) 260 (82.3 3.28 (2.35-4.57) 18 (8.1) 204 (91.9) 649 (96.3) 0.64 (0.42-0.98) Previously treated 796 (4.6) 16 537 (95. 1.39 (1.16-1.66) 190 (5.8) 3 065 (94.	•		EA			T.9T (T.T9-2.T/)	
18 (8.1) 204 (91.5) 1.44 (0.30-2.40) Other regions 25 (3.7) 649 (96.3) 0.64 (0.42-0.98) Previously treated 796 (4.6) 16 537 (95. 1.39 (1.16-1.66) 190 (5.8) 3 065 (94.			ica	19 (8.5)	205 (91.5	3.28 (2.35-4.57)	
Other regions 25 (3.7) 649 (96.3) 0.64 (0.42-0.98) Previously treated 796 (4.6) 16 537 (95. 1.39 (1.16-1.66) 190 (5.8) 3 065 (94.			ica	56 (17.7)	260 (82.3		
Previously treated 796 (4.6) 16 537 (95. 1.39 (1.16-1.66) 190 (5.8) 3 065 (94.				18 (8.1)	204 (91.9 ₇	1.44 (0.00-2.40)	
190 (5.8) 3 065 (94.		Other regions		25 (3.7)	649 (96.3)	0.64 (0.42-0.98)	
190 (5.8) 3 065 (94.				-			
190 (5.8) 3 065 (94.	Previously treated		796 (4.6)		16 537 (95.	95. 1.39 (1.16-1.66)	
	11001	busiy treated		190 (5.8)	3 065 (94.	=:35 (=:25 =:35)	
		_					
EXTRADULMONARY ry 781 (4.5) 16 572 (95. 1 21 11 50-7 19)	Extrapulmonary ry		781 (4.5)		16 572 (95.	1.81 (1.50-2.19)	
245 (7.2)					3 133 (92.	1.01 (1.30-2.13)	

Impact of HIV infection on treatment outcome of tuberculosis in Europe



HIV co-infected cases had a lower TB treatment success rate compared to HIV-negative cases (56.9% vs. 78.7% respectively; p<0.001).




Source: Karo et al. AIDS 2016

Treatment success of all TB cases notified in 2014, EU/EEA, 2015




72.0% of all TB cases* had a successful treatment outcome after 12 months (range 43.3–88.9%)



Treatment success in multidrug-resistant TB*, EU/EEA, 2015




40.4% was the success rate for all multidrug-resistant TB cases notified in 2013 (range 25.0–93.8%)



Treatment outcomes in MDR TB notified in 2011-2013, EU/EEA, 2015



Treatment success rates remained stable in the 2011, 2012 and 2013 cohorts



Summary



- Steady decrease of overall notification rate for past 20 years (3%/year), but increase in 5 countries (mainly in cases of foreign origin)
- Laboratory confirmation rate is 73% for new pulmonary, and 67% for all TB cases notified
- MDR TB: 4% of all TB cases reaching up to 21% in the Baltics
- Treatment success 72% for all TB cases reported in 2014
- MDR TB treatment success 40% for MDR TB cases reported in 2013

http://atlas.ecdc.europa.eu/public/index.aspx?Instance=GeneralAtlas

Acknowledgements



Nominated TB surveillance experts

Bernhard Benka, Maryse Wanlin, Tonka Varleva, Aleksandar Simunovic, Maria Koliou, Jiri Wallenfels, Peter Henrik Andersen, Piret Viiklepp, Hanna Soini, Jean-Paul Guthmann, Lena Fiebig, Ourania Kalkouni, Gábor Kovács, Thorsteinn Blondal, Joan O'Donnell, Francesco Paolo Maraglino, Dace Mihalovska, Edita Davidaviciene, Irene Demuth, Analita Pace-Asciak, Erika Slump, Trude Margrete Arnesen, Maria Korzeniewska-Koseła, Raquel Duarte, Domnica Chiotan, Ivan Solovic, Petra Svetina, Laura Sanchez-Cambronero Cejudo, Jerker Jonsson, Maeve Lalor